ArticleClinical ophthalmology (Auckland, N.Z.)2025
Effectiveness and Safety of Intravitreal Brolucizumab for Diabetic Macular Edema After Vitrectomy: A Before-and-After Study at a Specialized Center in Japan.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world efficacy and safety of Brolucizumab injection in vitrectomised eyes (BIVE) - a prospective multicentric study.BMC ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy and safety of intravitreal brolucizumab (IVBr), a vascular endothelial growth factor inhibitor, for injections in vitrectomized eyes with diabetic macular edema (DME) over 1 year. Patients and Methods: This retrospective before-and-after study analyzed 23 eyes of 20 patients with DME after vitrectomy. Outcomes assessed over 1 year included best-corrected visual acuity (BCVA), central subfield retinal thickness (CST), and the number of IVBr injections administered. The treatment protocol consisted of an initial IVBr injection followed by a pro re nata regimen. If CST did not improve after the last IVBr injection, treatment was switched to intravitreal triamcinolone acetonide injection (IVTA), sub-Tenon's triamcinolone acetonide (STTA) injection, or intravitreal faricimab (IVFa). Results: Seven eyes (30.4%) completed one-year IVBr treatment. There was no significant change in BCVA during the treatment period (LogMAR BCVA [mean±standard error]: baseline, 0.44±0.10; 6 months, 0.35±0.12 [P=0.22]; at 1 year, 0.37±0.11 [P=0.24]). However, CST (mean±standard error) significantly improved from baseline (558±36.3 μm) to 6 months (338±27.1 μm [P<0.05]) and 1 year (307±20.4 μm [P<0.05]). The mean number of IVBr injections was 3.6±1.3 (mean±standard deviation). Of the 16 eyes (69.6%) from 14 patients who did not complete one-year IVBr treatment, 11 eyes showed no CST improvement following the last IVBr injection, prompting a switch to IVTA, STTA, or IVFa in seven, one, or three eyes, respectively. Additionally, IVBr treatment was discontinued in one eye due to intraocular inflammation, while four patients (four eyes) dropped out within 1 year after starting treatment. Conclusion: Our findings demonstrated partial efficacy of IVBr in managing DME in vitrectomized eyes. However, variable responses often necessitate supplementary treatments to achieve therapeutic goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.